schliessen

Filtern

 

Bibliotheken

A Randomized Multicenter Open Label Blinded End Point Trial Comparing the Effects of Spironolactone to Chlorthalidone on Left Ventricular Mass in Patients with Early Stage Chronic Kidney Disease: Rationale and Design of the SPIRO-CKD trial

Abstract Background Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and arterial stiffness. In a previous trial, spironolactone improved these end points compared to placebo in subjects with early stage CKD, but it is not known whether these effects were specific... Full description

Journal Title: The American heart journal 2017, Vol.191, p.37-46
Main Author: Hayer, MK, MB, ChB
Other Authors: Edwards, NC, PhD , Slinn, G, M Phil , Moody, WE, PhD , Steeds, RP, MD , Ferro, CJ, PhD , Price, A, MB, ChB , Anduja, C, RN , Dutton, M, MSc , Webster, R, PhD , Webb, DJ, DSc , Semple, S, PhD , MacIntyre, IM, PhD , Melville, V, PhD , Wilkinson, IB, DM , Hiemstra, TF, PhD , Wheeler, DC, MD , Herrey, A, PhD , Grant, M, PhD , Mehta, S, MSc , Ives, N, MSc , Townend, JN, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
NMR
Quelle: Alma/SFX Local Collection
Publisher: United States: Elsevier Inc
ID: ISSN: 0002-8703
Link: https://www.ncbi.nlm.nih.gov/pubmed/28888268
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5603966
title: A Randomized Multicenter Open Label Blinded End Point Trial Comparing the Effects of Spironolactone to Chlorthalidone on Left Ventricular Mass in Patients with Early Stage Chronic Kidney Disease: Rationale and Design of the SPIRO-CKD trial
format: Article
creator:
  • Hayer, MK, MB, ChB
  • Edwards, NC, PhD
  • Slinn, G, M Phil
  • Moody, WE, PhD
  • Steeds, RP, MD
  • Ferro, CJ, PhD
  • Price, A, MB, ChB
  • Anduja, C, RN
  • Dutton, M, MSc
  • Webster, R, PhD
  • Webb, DJ, DSc
  • Semple, S, PhD
  • MacIntyre, IM, PhD
  • Melville, V, PhD
  • Wilkinson, IB, DM
  • Hiemstra, TF, PhD
  • Wheeler, DC, MD
  • Herrey, A, PhD
  • Grant, M, PhD
  • Mehta, S, MSc
  • Ives, N, MSc
  • Townend, JN, MD
subjects:
  • Adult
  • Aged
  • Analysis
  • Angiotensin
  • Angiotensin-converting enzyme inhibitors
  • Blind Method
  • Blood
  • Blood pressure
  • Cardiomyopathy
  • Cardiovascular
  • Cardiovascular disease
  • Care and treatment
  • Chlorthalidone
  • Chlorthalidone - administration & dosage
  • Chronic
  • Chronic kidney failure
  • Cine
  • Clinical trials
  • Combination
  • Conversion
  • Design
  • Diagnostic imaging
  • Dose
  • Dose-Response Relationship, Drug
  • Drug
  • Drug Therapy
  • Drug Therapy, Combination
  • Enzyme inhibitors
  • Enzymes
  • Female
  • Follow
  • Follow-Up Studies
  • Heart
  • Heart diseases
  • Heart failure
  • Heart Ventricles
  • Heart Ventricles - diagnostic imaging
  • Heart Ventricles - physiopathology
  • Humans
  • Hypertension
  • Hypertrophy
  • Hypertrophy, Left Ventricular - etiology
  • Hypertrophy, Left Ventricular - mortality
  • Hypertrophy, Left Ventricular - physiopathology
  • Journal Article
  • Kidney diseases
  • Kidney Failure
  • Kidney Failure, Chronic - complications
  • Kidney Failure, Chronic - mortality
  • Kidney Failure, Chronic - physiopathology
  • Kidney transplantation
  • Laboratory tests
  • Left Ventricular
  • Magnetic Resonance Imaging
  • Magnetic Resonance Imaging, Cine
  • Male
  • Medical research
  • Medicine, Experimental
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists
  • Mineralocorticoid Receptor Antagonists - administration & dosage
  • Mortality
  • Multicenter Study
  • NMR
  • Nuclear magnetic resonance
  • omized Controlled Trial
  • Patients
  • Peptidyl-dipeptidase A
  • Prospective Studies
  • Pulse Wave Analysis
  • Randomization
  • Recruitment
  • Response Relationship
  • Rodents
  • Single
  • Single-Blind Method
  • Sodium Chloride Symporter Inhibitors
  • Sodium Chloride Symporter Inhibitors - administration & dosage
  • Spironolactone
  • Spironolactone - administration & dosage
  • Stiffness
  • Studies
  • Survival Rate
  • Survival Rate - trends
  • Time Factors
  • Treatment Outcome
  • Trial Design
  • United States
  • United States - epidemiology
  • Up Studies
  • Vascular Stiffness
  • Velocity
  • Ventricle
  • Wave propagation
  • Wave velocity
ispartof: The American heart journal, 2017, Vol.191, p.37-46
description: Abstract Background Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and arterial stiffness. In a previous trial, spironolactone improved these end points compared to placebo in subjects with early stage CKD, but it is not known whether these effects were specific to the drug or secondary to blood pressure lowering. Aim To investigate the hypothesis that spironolactone is superior to chlorthalidone in the reduction of LV mass while exerting similar effects on blood pressure. Design. This is a multi-center, prospective, randomized open-label blinded endpoint (PROBE) clinical trial initially designed to compare the effects of 40 weeks of treatment with spironolactone 25 mg once daily to chlorthalidone 25 mg once daily on the co-primary end points of change in pulse wave velocity and change in LV mass in 350 patients with stages 2 and 3 CKD on established treatment with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker. Due to slow recruitment rates it became apparent that it would not be possible to recruit this sample size within the funded time period. The study design was therefore changed to one with a single primary end-point of LV mass requiring 150 patients. Recruitment was completed on 31st December 2016 at which time 154 patients had been recruited. Investigations included cardiac magnetic resonance imaging, applanation tonometry, 24-hour ambulatory blood pressure monitoring, and laboratory tests. Subjects are assessed before and after 40 weeks of randomly allocated drug therapy and at 46 weeks after discontinuation of the study drug.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0002-8703
fulltext: fulltext
issn:
  • 0002-8703
  • 1097-6744
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.545589
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5603966
sourceformatXML
sourcesystemPC
galeidA504284944
sourcerecordidA504284944
originalsourceidFETCH-LOGICAL-1742t-7e0e2956eb752b5216b7a38eeb63eb64a8be6b0c37d941955dd69c894d92fff53
addsrcrecordideNqNU2tv0zAUjRCIjcEP4AuyxOcWOy_HIE0qXYFpG5vWwVfLcW5al9Qutrup_Gn-Ajfq2ANNQKLIin3u8bmPkyQvGR0yyso3i6GaL4YpZXxIiyGl1aNkl1HBByXP88fJLqU0HVScZjvJsxAW-FumVfk02UkrfNKy2k1-jsi5so1bmh_QkJN1F40GG8GT0xVYcqxq6Mj7ztgGjye2IWfO2EguvFEdGbvlSnljZyTOgUzaFnQMxLVkujLeWdcpHZ0FEh0Zzzvn41x1pul3HFJDG8lXvMsbve6UJycqBGIsOVPR4HYgVybOyUT5bkOmUc0ASZDVaHJkGgsbcmACqABvMYNonFUdEEyFHEAwM9vL6FVNzw7PTwfjowMSe83Pkyet6gK8uF73ki8fJhfjT4Pj04-H49HxgPE8jQMOFFJRlFDzIq2LlJU1V1kFUJcZfrmqaihrqjPeiJyJomiaUuhK5I1I27Ytsr1kf8u7WtdLaPqaetXJlTdL5TfSKSPvn1gzlzN3KYuSZqIskeDzlsBhH5TxcC8W848SW7JeyatWUspkyzkKpUJwQIXQ8jStKC2g1TzLWdog4etrRd59X0OIcuHWHqsWJBMZ56VgrLhFzbCc0tjWoTq9NEHLUcEEzlop_oGieVrlIs8RNXwAhW8DS6NxDFqD-_do_y_gzg2vHgiQdxkfBtxhYFuA9i4ED-1NmRmVvcnkQqLJZG8ySQssdXVLuu3gTcRvVyHg3RYAOGGXBrwMGkdaQ4N91Ng4Z_5Kv_9HtEb_Ga26b7CBcNs1GVJJ5bR3eW9yxjPKcsGzXyMzSUU
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1937769115
display
typearticle
titleA Randomized Multicenter Open Label Blinded End Point Trial Comparing the Effects of Spironolactone to Chlorthalidone on Left Ventricular Mass in Patients with Early Stage Chronic Kidney Disease: Rationale and Design of the SPIRO-CKD trial
sourceAlma/SFX Local Collection
creatorHayer, MK, MB, ChB ; Edwards, NC, PhD ; Slinn, G, M Phil ; Moody, WE, PhD ; Steeds, RP, MD ; Ferro, CJ, PhD ; Price, A, MB, ChB ; Anduja, C, RN ; Dutton, M, MSc ; Webster, R, PhD ; Webb, DJ, DSc ; Semple, S, PhD ; MacIntyre, IM, PhD ; Melville, V, PhD ; Wilkinson, IB, DM ; Hiemstra, TF, PhD ; Wheeler, DC, MD ; Herrey, A, PhD ; Grant, M, PhD ; Mehta, S, MSc ; Ives, N, MSc ; Townend, JN, MD
creatorcontribHayer, MK, MB, ChB ; Edwards, NC, PhD ; Slinn, G, M Phil ; Moody, WE, PhD ; Steeds, RP, MD ; Ferro, CJ, PhD ; Price, A, MB, ChB ; Anduja, C, RN ; Dutton, M, MSc ; Webster, R, PhD ; Webb, DJ, DSc ; Semple, S, PhD ; MacIntyre, IM, PhD ; Melville, V, PhD ; Wilkinson, IB, DM ; Hiemstra, TF, PhD ; Wheeler, DC, MD ; Herrey, A, PhD ; Grant, M, PhD ; Mehta, S, MSc ; Ives, N, MSc ; Townend, JN, MD
descriptionAbstract Background Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and arterial stiffness. In a previous trial, spironolactone improved these end points compared to placebo in subjects with early stage CKD, but it is not known whether these effects were specific to the drug or secondary to blood pressure lowering. Aim To investigate the hypothesis that spironolactone is superior to chlorthalidone in the reduction of LV mass while exerting similar effects on blood pressure. Design. This is a multi-center, prospective, randomized open-label blinded endpoint (PROBE) clinical trial initially designed to compare the effects of 40 weeks of treatment with spironolactone 25 mg once daily to chlorthalidone 25 mg once daily on the co-primary end points of change in pulse wave velocity and change in LV mass in 350 patients with stages 2 and 3 CKD on established treatment with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker. Due to slow recruitment rates it became apparent that it would not be possible to recruit this sample size within the funded time period. The study design was therefore changed to one with a single primary end-point of LV mass requiring 150 patients. Recruitment was completed on 31st December 2016 at which time 154 patients had been recruited. Investigations included cardiac magnetic resonance imaging, applanation tonometry, 24-hour ambulatory blood pressure monitoring, and laboratory tests. Subjects are assessed before and after 40 weeks of randomly allocated drug therapy and at 46 weeks after discontinuation of the study drug.
identifier
0ISSN: 0002-8703
1EISSN: 1097-6744
2DOI: 10.1016/j.ahj.2017.05.008
3PMID: 28888268
languageeng
publisherUnited States: Elsevier Inc
subjectAdult ; Aged ; Analysis ; Angiotensin ; Angiotensin-converting enzyme inhibitors ; Blind Method ; Blood ; Blood pressure ; Cardiomyopathy ; Cardiovascular ; Cardiovascular disease ; Care and treatment ; Chlorthalidone ; Chlorthalidone - administration & dosage ; Chronic ; Chronic kidney failure ; Cine ; Clinical trials ; Combination ; Conversion ; Design ; Diagnostic imaging ; Dose ; Dose-Response Relationship, Drug ; Drug ; Drug Therapy ; Drug Therapy, Combination ; Enzyme inhibitors ; Enzymes ; Female ; Follow ; Follow-Up Studies ; Heart ; Heart diseases ; Heart failure ; Heart Ventricles ; Heart Ventricles - diagnostic imaging ; Heart Ventricles - physiopathology ; Humans ; Hypertension ; Hypertrophy ; Hypertrophy, Left Ventricular - etiology ; Hypertrophy, Left Ventricular - mortality ; Hypertrophy, Left Ventricular - physiopathology ; Journal Article ; Kidney diseases ; Kidney Failure ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - mortality ; Kidney Failure, Chronic - physiopathology ; Kidney transplantation ; Laboratory tests ; Left Ventricular ; Magnetic Resonance Imaging ; Magnetic Resonance Imaging, Cine ; Male ; Medical research ; Medicine, Experimental ; Middle Aged ; Mineralocorticoid Receptor Antagonists ; Mineralocorticoid Receptor Antagonists - administration & dosage ; Mortality ; Multicenter Study ; NMR ; Nuclear magnetic resonance ; omized Controlled Trial ; Patients ; Peptidyl-dipeptidase A ; Prospective Studies ; Pulse Wave Analysis ; Randomization ; Recruitment ; Response Relationship ; Rodents ; Single ; Single-Blind Method ; Sodium Chloride Symporter Inhibitors ; Sodium Chloride Symporter Inhibitors - administration & dosage ; Spironolactone ; Spironolactone - administration & dosage ; Stiffness ; Studies ; Survival Rate ; Survival Rate - trends ; Time Factors ; Treatment Outcome ; Trial Design ; United States ; United States - epidemiology ; Up Studies ; Vascular Stiffness ; Velocity ; Ventricle ; Wave propagation ; Wave velocity
ispartofThe American heart journal, 2017, Vol.191, p.37-46
rights
02018 The Authors
1Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
2COPYRIGHT 2017 Elsevier B.V.
3Copyright Elsevier Limited Sep 1, 2017
42017 The Authors 2017
lds50peer_reviewed
oafree_for_read
orcidid0000-0002-2115-8689 ; 0000-0001-6598-9399
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28888268$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Hayer, MK, MB, ChB
1Edwards, NC, PhD
2Slinn, G, M Phil
3Moody, WE, PhD
4Steeds, RP, MD
5Ferro, CJ, PhD
6Price, A, MB, ChB
7Anduja, C, RN
8Dutton, M, MSc
9Webster, R, PhD
10Webb, DJ, DSc
11Semple, S, PhD
12MacIntyre, IM, PhD
13Melville, V, PhD
14Wilkinson, IB, DM
15Hiemstra, TF, PhD
16Wheeler, DC, MD
17Herrey, A, PhD
18Grant, M, PhD
19Mehta, S, MSc
20Ives, N, MSc
21Townend, JN, MD
title
0A Randomized Multicenter Open Label Blinded End Point Trial Comparing the Effects of Spironolactone to Chlorthalidone on Left Ventricular Mass in Patients with Early Stage Chronic Kidney Disease: Rationale and Design of the SPIRO-CKD trial
1The American heart journal
addtitleAm Heart J
descriptionAbstract Background Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and arterial stiffness. In a previous trial, spironolactone improved these end points compared to placebo in subjects with early stage CKD, but it is not known whether these effects were specific to the drug or secondary to blood pressure lowering. Aim To investigate the hypothesis that spironolactone is superior to chlorthalidone in the reduction of LV mass while exerting similar effects on blood pressure. Design. This is a multi-center, prospective, randomized open-label blinded endpoint (PROBE) clinical trial initially designed to compare the effects of 40 weeks of treatment with spironolactone 25 mg once daily to chlorthalidone 25 mg once daily on the co-primary end points of change in pulse wave velocity and change in LV mass in 350 patients with stages 2 and 3 CKD on established treatment with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker. Due to slow recruitment rates it became apparent that it would not be possible to recruit this sample size within the funded time period. The study design was therefore changed to one with a single primary end-point of LV mass requiring 150 patients. Recruitment was completed on 31st December 2016 at which time 154 patients had been recruited. Investigations included cardiac magnetic resonance imaging, applanation tonometry, 24-hour ambulatory blood pressure monitoring, and laboratory tests. Subjects are assessed before and after 40 weeks of randomly allocated drug therapy and at 46 weeks after discontinuation of the study drug.
subject
0Adult
1Aged
2Analysis
3Angiotensin
4Angiotensin-converting enzyme inhibitors
5Blind Method
6Blood
7Blood pressure
8Cardiomyopathy
9Cardiovascular
10Cardiovascular disease
11Care and treatment
12Chlorthalidone
13Chlorthalidone - administration & dosage
14Chronic
15Chronic kidney failure
16Cine
17Clinical trials
18Combination
19Conversion
20Design
21Diagnostic imaging
22Dose
23Dose-Response Relationship, Drug
24Drug
25Drug Therapy
26Drug Therapy, Combination
27Enzyme inhibitors
28Enzymes
29Female
30Follow
31Follow-Up Studies
32Heart
33Heart diseases
34Heart failure
35Heart Ventricles
36Heart Ventricles - diagnostic imaging
37Heart Ventricles - physiopathology
38Humans
39Hypertension
40Hypertrophy
41Hypertrophy, Left Ventricular - etiology
42Hypertrophy, Left Ventricular - mortality
43Hypertrophy, Left Ventricular - physiopathology
44Journal Article
45Kidney diseases
46Kidney Failure
47Kidney Failure, Chronic - complications
48Kidney Failure, Chronic - mortality
49Kidney Failure, Chronic - physiopathology
50Kidney transplantation
51Laboratory tests
52Left Ventricular
53Magnetic Resonance Imaging
54Magnetic Resonance Imaging, Cine
55Male
56Medical research
57Medicine, Experimental
58Middle Aged
59Mineralocorticoid Receptor Antagonists
60Mineralocorticoid Receptor Antagonists - administration & dosage
61Mortality
62Multicenter Study
63NMR
64Nuclear magnetic resonance
65omized Controlled Trial
66Patients
67Peptidyl-dipeptidase A
68Prospective Studies
69Pulse Wave Analysis
70Randomization
71Recruitment
72Response Relationship
73Rodents
74Single
75Single-Blind Method
76Sodium Chloride Symporter Inhibitors
77Sodium Chloride Symporter Inhibitors - administration & dosage
78Spironolactone
79Spironolactone - administration & dosage
80Stiffness
81Studies
82Survival Rate
83Survival Rate - trends
84Time Factors
85Treatment Outcome
86Trial Design
87United States
88United States - epidemiology
89Up Studies
90Vascular Stiffness
91Velocity
92Ventricle
93Wave propagation
94Wave velocity
issn
00002-8703
11097-6744
fulltexttrue
rsrctypearticle
creationdate2017
recordtypearticle
recordideNqNU2tv0zAUjRCIjcEP4AuyxOcWOy_HIE0qXYFpG5vWwVfLcW5al9Qutrup_Gn-Ajfq2ANNQKLIin3u8bmPkyQvGR0yyso3i6GaL4YpZXxIiyGl1aNkl1HBByXP88fJLqU0HVScZjvJsxAW-FumVfk02UkrfNKy2k1-jsi5so1bmh_QkJN1F40GG8GT0xVYcqxq6Mj7ztgGjye2IWfO2EguvFEdGbvlSnljZyTOgUzaFnQMxLVkujLeWdcpHZ0FEh0Zzzvn41x1pul3HFJDG8lXvMsbve6UJycqBGIsOVPR4HYgVybOyUT5bkOmUc0ASZDVaHJkGgsbcmACqABvMYNonFUdEEyFHEAwM9vL6FVNzw7PTwfjowMSe83Pkyet6gK8uF73ki8fJhfjT4Pj04-H49HxgPE8jQMOFFJRlFDzIq2LlJU1V1kFUJcZfrmqaihrqjPeiJyJomiaUuhK5I1I27Ytsr1kf8u7WtdLaPqaetXJlTdL5TfSKSPvn1gzlzN3KYuSZqIskeDzlsBhH5TxcC8W848SW7JeyatWUspkyzkKpUJwQIXQ8jStKC2g1TzLWdog4etrRd59X0OIcuHWHqsWJBMZ56VgrLhFzbCc0tjWoTq9NEHLUcEEzlop_oGieVrlIs8RNXwAhW8DS6NxDFqD-_do_y_gzg2vHgiQdxkfBtxhYFuA9i4ED-1NmRmVvcnkQqLJZG8ySQssdXVLuu3gTcRvVyHg3RYAOGGXBrwMGkdaQ4N91Ng4Z_5Kv_9HtEb_Ga26b7CBcNs1GVJJ5bR3eW9yxjPKcsGzXyMzSUU
startdate2017
enddate2017
creator
0Hayer, MK, MB, ChB
1Edwards, NC, PhD
2Slinn, G, M Phil
3Moody, WE, PhD
4Steeds, RP, MD
5Ferro, CJ, PhD
6Price, A, MB, ChB
7Anduja, C, RN
8Dutton, M, MSc
9Webster, R, PhD
10Webb, DJ, DSc
11Semple, S, PhD
12MacIntyre, IM, PhD
13Melville, V, PhD
14Wilkinson, IB, DM
15Hiemstra, TF, PhD
16Wheeler, DC, MD
17Herrey, A, PhD
18Grant, M, PhD
19Mehta, S, MSc
20Ives, N, MSc
21Townend, JN, MD
general
0Elsevier Inc
1Elsevier B.V
2Elsevier Limited
3American Heart Journal
4Mosby
scope
06I.
1AAFTH
2CGR
3CUY
4CVF
5ECM
6EIF
7NPM
8AAYXX
9CITATION
10BKMMT
11BSHEE
123V.
137QO
147RV
157TS
167X7
177XB
1888C
1988E
208AO
218C1
228FD
238FI
248FJ
258FK
268G5
27ABUWG
28AN0
29AZQEC
30BENPR
31DWQXO
32FR3
33FYUFA
34GHDGH
35GNUQQ
36GUQSH
37K9.
38KB0
39M0S
40M0T
41M1P
42M2O
43MBDVC
44NAPCQ
45P64
46PADUT
47PQEST
48PQQKQ
49PQUKI
50PRINS
51Q9U
52BOBZL
53CLFQK
545PM
orcidid
0https://orcid.org/0000-0002-2115-8689
1https://orcid.org/0000-0001-6598-9399
sort
creationdate2017
titleA Randomized Multicenter Open Label Blinded End Point Trial Comparing the Effects of Spironolactone to Chlorthalidone on Left Ventricular Mass in Patients with Early Stage Chronic Kidney Disease: Rationale and Design of the SPIRO-CKD trial
authorHayer, MK, MB, ChB ; Edwards, NC, PhD ; Slinn, G, M Phil ; Moody, WE, PhD ; Steeds, RP, MD ; Ferro, CJ, PhD ; Price, A, MB, ChB ; Anduja, C, RN ; Dutton, M, MSc ; Webster, R, PhD ; Webb, DJ, DSc ; Semple, S, PhD ; MacIntyre, IM, PhD ; Melville, V, PhD ; Wilkinson, IB, DM ; Hiemstra, TF, PhD ; Wheeler, DC, MD ; Herrey, A, PhD ; Grant, M, PhD ; Mehta, S, MSc ; Ives, N, MSc ; Townend, JN, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1742t-7e0e2956eb752b5216b7a38eeb63eb64a8be6b0c37d941955dd69c894d92fff53
rsrctypearticles
prefilterarticles
languageeng
creationdate2017
topic
0Adult
1Aged
2Analysis
3Angiotensin
4Angiotensin-converting enzyme inhibitors
5Blind Method
6Blood
7Blood pressure
8Cardiomyopathy
9Cardiovascular
10Cardiovascular disease
11Care and treatment
12Chlorthalidone
13Chlorthalidone - administration & dosage
14Chronic
15Chronic kidney failure
16Cine
17Clinical trials
18Combination
19Conversion
20Design
21Diagnostic imaging
22Dose
23Dose-Response Relationship, Drug
24Drug
25Drug Therapy
26Drug Therapy, Combination
27Enzyme inhibitors
28Enzymes
29Female
30Follow
31Follow-Up Studies
32Heart
33Heart diseases
34Heart failure
35Heart Ventricles
36Heart Ventricles - diagnostic imaging
37Heart Ventricles - physiopathology
38Humans
39Hypertension
40Hypertrophy
41Hypertrophy, Left Ventricular - etiology
42Hypertrophy, Left Ventricular - mortality
43Hypertrophy, Left Ventricular - physiopathology
44Journal Article
45Kidney diseases
46Kidney Failure
47Kidney Failure, Chronic - complications
48Kidney Failure, Chronic - mortality
49Kidney Failure, Chronic - physiopathology
50Kidney transplantation
51Laboratory tests
52Left Ventricular
53Magnetic Resonance Imaging
54Magnetic Resonance Imaging, Cine
55Male
56Medical research
57Medicine, Experimental
58Middle Aged
59Mineralocorticoid Receptor Antagonists
60Mineralocorticoid Receptor Antagonists - administration & dosage
61Mortality
62Multicenter Study
63NMR
64Nuclear magnetic resonance
65omized Controlled Trial
66Patients
67Peptidyl-dipeptidase A
68Prospective Studies
69Pulse Wave Analysis
70Randomization
71Recruitment
72Response Relationship
73Rodents
74Single
75Single-Blind Method
76Sodium Chloride Symporter Inhibitors
77Sodium Chloride Symporter Inhibitors - administration & dosage
78Spironolactone
79Spironolactone - administration & dosage
80Stiffness
81Studies
82Survival Rate
83Survival Rate - trends
84Time Factors
85Treatment Outcome
86Trial Design
87United States
88United States - epidemiology
89Up Studies
90Vascular Stiffness
91Velocity
92Ventricle
93Wave propagation
94Wave velocity
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Hayer, MK, MB, ChB
1Edwards, NC, PhD
2Slinn, G, M Phil
3Moody, WE, PhD
4Steeds, RP, MD
5Ferro, CJ, PhD
6Price, A, MB, ChB
7Anduja, C, RN
8Dutton, M, MSc
9Webster, R, PhD
10Webb, DJ, DSc
11Semple, S, PhD
12MacIntyre, IM, PhD
13Melville, V, PhD
14Wilkinson, IB, DM
15Hiemstra, TF, PhD
16Wheeler, DC, MD
17Herrey, A, PhD
18Grant, M, PhD
19Mehta, S, MSc
20Ives, N, MSc
21Townend, JN, MD
collection
0ScienceDirect Open Access Titles
1Elsevier:ScienceDirect:Open Access
2Medline
3MEDLINE
4MEDLINE (Ovid)
5MEDLINE
6MEDLINE
7PubMed
8CrossRef
9Gale General OneFile (A&I only)
10Academic OneFile (A&I only)
11ProQuest Central (Corporate)
12Biotechnology Research Abstracts
13Nursing & Allied Health Database
14Physical Education Index
15Health & Medical Collection
16ProQuest Central (purchase pre-March 2016)
17Healthcare Administration Database (Alumni)
18Medical Database (Alumni Edition)
19ProQuest Pharma Collection
20Public Health Database
21Technology Research Database
22Hospital Premium Collection
23Hospital Premium Collection (Alumni Edition)
24ProQuest Central (Alumni) (purchase pre-March 2016)
25Research Library (Alumni Edition)
26ProQuest Central (Alumni Edition)
27British Nursing Database
28ProQuest Central Essentials
29ProQuest Central
30ProQuest Central Korea
31Engineering Research Database
32Health Research Premium Collection
33Health Research Premium Collection (Alumni)
34ProQuest Central Student
35Research Library Prep
36ProQuest Health & Medical Complete (Alumni)
37Nursing & Allied Health Database (Alumni Edition)
38Health & Medical Collection (Alumni Edition)
39Healthcare Administration Database
40Medical Database
41Research Library
42Research Library (Corporate)
43Nursing & Allied Health Premium
44Biotechnology and BioEngineering Abstracts
45Research Library China
46ProQuest One Academic Eastern Edition
47ProQuest One Academic
48ProQuest One Academic UKI Edition
49ProQuest Central China
50ProQuest Central Basic
51OpenAIRE (Open Access)
52OpenAIRE
53PubMed Central (Full Participant titles)
jtitleThe American heart journal
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Hayer, MK, MB, ChB
1Edwards, NC, PhD
2Slinn, G, M Phil
3Moody, WE, PhD
4Steeds, RP, MD
5Ferro, CJ, PhD
6Price, A, MB, ChB
7Anduja, C, RN
8Dutton, M, MSc
9Webster, R, PhD
10Webb, DJ, DSc
11Semple, S, PhD
12MacIntyre, IM, PhD
13Melville, V, PhD
14Wilkinson, IB, DM
15Hiemstra, TF, PhD
16Wheeler, DC, MD
17Herrey, A, PhD
18Grant, M, PhD
19Mehta, S, MSc
20Ives, N, MSc
21Townend, JN, MD
formatjournal
genrearticle
ristypeJOUR
atitleA Randomized Multicenter Open Label Blinded End Point Trial Comparing the Effects of Spironolactone to Chlorthalidone on Left Ventricular Mass in Patients with Early Stage Chronic Kidney Disease: Rationale and Design of the SPIRO-CKD trial
jtitleThe American heart journal
addtitleAm Heart J
date2017
risdate2017
volume191
spage37
epage46
pages37-46
issn0002-8703
eissn1097-6744
abstractAbstract Background Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and arterial stiffness. In a previous trial, spironolactone improved these end points compared to placebo in subjects with early stage CKD, but it is not known whether these effects were specific to the drug or secondary to blood pressure lowering. Aim To investigate the hypothesis that spironolactone is superior to chlorthalidone in the reduction of LV mass while exerting similar effects on blood pressure. Design. This is a multi-center, prospective, randomized open-label blinded endpoint (PROBE) clinical trial initially designed to compare the effects of 40 weeks of treatment with spironolactone 25 mg once daily to chlorthalidone 25 mg once daily on the co-primary end points of change in pulse wave velocity and change in LV mass in 350 patients with stages 2 and 3 CKD on established treatment with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker. Due to slow recruitment rates it became apparent that it would not be possible to recruit this sample size within the funded time period. The study design was therefore changed to one with a single primary end-point of LV mass requiring 150 patients. Recruitment was completed on 31st December 2016 at which time 154 patients had been recruited. Investigations included cardiac magnetic resonance imaging, applanation tonometry, 24-hour ambulatory blood pressure monitoring, and laboratory tests. Subjects are assessed before and after 40 weeks of randomly allocated drug therapy and at 46 weeks after discontinuation of the study drug.
copUnited States
pubElsevier Inc
pmid28888268
doi10.1016/j.ahj.2017.05.008
orcidid
0https://orcid.org/0000-0002-2115-8689
1https://orcid.org/0000-0001-6598-9399
oafree_for_read